Agenus shared a post on LinkedIn:
“Agenus reported first quarter 2026 financial results and provided an update on BOT+BAL execution across global access and Phase 3 development today.
Q1 marked a transition from foundation-building to execution:
- Physician-initiated interest through regulatory-authorized access pathways continued to broaden
- Phase 3 BATTMAN trial commenced patient enrollment in April 2026
- Zydus collaboration closed, strengthening the balance sheet and securing dedicated U.S. biologics manufacturing capacity
- Agenus continues to align operating priorities around BOT+BAL, financial discipline and commercial readiness
BOT+BAL remains one of the most clinically advanced next-generation CTLA-4/PD-1 combinations in development.
Read the full release here.”
Other articles about Agenus on OncoDaily.
